David A. Siegel Seagen Inc. Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $5.99 Million - $6.77 Million	31,300 Added 94.28%	64,500 $13.7 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $6.23 Million - $6.85 Million	33,200 New	33,200 $6.39 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $1.46 Million - $1.73 Million	12,400 New	12,400 $1.59 Million
Q2 2021 Aug 16, 2021	SELL	$135.08 - $161.1 $13.8 Million - $16.4 Million	-101,900 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $14 Million - $19.4 Million	101,900 New	101,900 $14.2 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.